Orexigen Therapeutics, Inc. 4
4 · Orexigen Therapeutics, Inc. · Filed Feb 11, 2014
Insider Transaction Report
Form 4
Booth Mark D
Chief Commercial Officer
Transactions
- Award
Stock Option (right to buy)
2014-02-07+205,000→ 205,000 totalExercise: $6.30Exp: 2024-02-06→ Common Stock (205,000 underlying) - Award
Common Stock
2013-11-29$5.34/sh+3,810$20,345→ 3,810 total
Footnotes (3)
- [F1]These shares were acquired under the Company's Employee Stock Purchase Plan.
- [F2]1/48th of the shares of stock subject to the option (rounded down to the next whole number of shares) shall vest on the same day of each month following 2/7/2014, so that all of the shares of the stock subject to the option shall be vested on 2/7/2018, subject to the reporting person's continued service relationship (whether as an employee, director or consultant) with the Company or any parent or subsidiary on each such date.
- [F3]Not applicable.